Peptide Pro Solutions FAQ
Some questions concern a measured result; others ask an experiment to answer something it never tested. The distinction matters most for combinations.
CJC-1295, ipamorelin and tesamorelin together?
The studies here provide no controlled human trial of the three together. Tesamorelin and CJC-1295 act at the GHRH receptor; ipamorelin acts at the ghrelin receptor. The engineered-cell experiment on receptor co-activation gives a reason to investigate interacting signals. Its cAMP measurement supplies no clinical test of this proposed three-compound combination.
I doubt a tesamorelin addition makes that clinical answer easier. Tesamorelin’s visceral-fat result during continued treatment comes from tesamorelin trials in adults with HIV. The combination has its own unanswered questions about benefit, exposure and harm.
What does prolonged stimulation by CJC-1295 mean?
The paper titled “Prolonged stimulation” tested CJC-1295 with DAC alone in healthy adults. Growth hormone rose two- to ten-fold for at least six days; IGF-1 remained elevated for nine to eleven days. After multiple study doses, IGF-1 stayed above baseline for up to 28 days.
Those are durations of measured hormonal changes. No controlled trial establishes a timetable for better sleep, recovery or fat loss from CJC-1295 with ipamorelin. The pairing page discusses why the DAC form matters.
What research concerns CJC-1295 in children?
The prolonged-stimulation study enrolled healthy adults. The ipamorelin bone-growth paper used adult female rats. Neither provides a pediatric treatment result for CJC-1295/ipamorelin.
My answer stops there because the populations matter to the question. Neither research compound has approval for human use, including use in children.
CJC-1295/ipamorelin for endometriosis?
The human studies collected here do not test the pair for endometriosis. The ipamorelin clinical trial concerns adults undergoing bowel resection, while the CJC-1295 study concerns hormone secretion in healthy adults. The combination itself lacks a controlled human outcome trial.
An explanation involving hormones cannot establish an endometriosis benefit from these studies. For endometriosis, I reserve judgment until a direct clinical result exists.
What is an ipamorelin acetate research compound?
Ipamorelin acetate is a salt form of the synthetic peptide. Its founding rat and swine experiments characterized selective growth-hormone release. Acetate in the name describes the chemical form; it provides no assurance of contents, sterility or a human health effect.
CJC-1295 research compound descriptions also need the DAC distinction: the prolonged-stimulation study tested the albumin-binding form. Source descriptions and compound names cannot fill the missing clinical trial of the pair.
What follows tesamorelin discontinuation?
Visceral fat reaccumulated after discontinuation in the 52-week tesamorelin program. Its -18% reduction was sustained during continued treatment. The continuing-treatment condition dominates my assessment of tesamorelin.
The approved use concerns excess abdominal fat in adults with HIV-associated lipodystrophy. The approval and liver-safety monograph sets out that limited indication. General weight-loss claims go beyond it.
Which adverse effects have been measured?
The growth hormone secretagogue review identifies blood-glucose elevation from reduced insulin sensitivity as a concern, and asks for longer data on cancer and mortality. Growth-hormone excess can also cause fluid retention and joint discomfort. The rat heart-injury study tested a different ghrelin-receptor agonist, so it raises a class question rather than reporting ipamorelin injury.
Reports of sleep changes, soreness, hunger, flushing, tingling and puffiness with ipamorelin or the pair are anecdotal accounts, not clinical evidence. They cannot establish cause or reliable adverse-event rates. The combination has no controlled human safety study.
For tesamorelin, active cancer is a labeled contraindication, and longer-term cancer safety remains limited. The 52-week glucose observations were judged not clinically significant within that program.
Doses and pharmacy ingredient rules
Neither CJC-1295 nor ipamorelin has an approved human dose or approved human use. No controlled trial establishes a dose for the pair, and the studies supply no personal schedule.
On FDA’s page current as of April 22, 2026, both appear among withdrawn 503A nominations. Ipamorelin acetate also remains in Category 2 under the 503B interim policy, without the policy’s interim allowance. FDA gives no withdrawal date. Withdrawal is no finding of safety and does not itself settle permission to compound. Neither ipamorelin form is on the 503A Bulks List. WADA prohibits all three compounds at all times in sport.